Wavehist 48 Tablet contains Betahistine 48mg, a clinically proven vestibular suppressant and vasodilator primarily used for the management of vertigo, Ménière’s disease, and balance disorders. It works by improving blood flow in the inner ear, reducing the frequency and severity of vertigo attacks, and restoring equilibrium.
The formulation helps in alleviating symptoms such as dizziness, nausea, tinnitus, and imbalance, enhancing patient mobility and quality of life. Betahistine 48mg improves microcirculation in the inner ear, helping to normalize vestibular function and reduce inner ear pressure, which is critical for long-term symptom control.
Belonging to the neurology and ENT segment, Wavehist 48 Tablet is in high demand among ENT specialists, neurologists, hospitals, and PCD pharma franchise networks. Its proven efficacy, tolerable safety profile, and long-term therapeutic benefits make it a preferred choice for managing vestibular disorders.
For PCD franchise partners, Wavehist 48 Tablet offers a high-demand, profitable opportunity. Its established clinical reputation in vertigo management, coupled with strong B2B distribution potential, ensures consistent business growth across both domestic and export pharma markets.